Details of the Drug Combination

General Information of Drug Combination (ID: DCLS851)

• Drug Combination Name: Misoprostol + Oxytocin
• Indication: Vaginal Delivery; Status: Phase 1 [1]
• Component Drugs:
  Misoprostol (DMHVJFK): Small molecular drug
  Oxytocin (DMDL27I): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Misoprostol

Disease Entry	ICD 11	Status	REF
Medical abortion	JA00.1Z	Approved	[2]
Postpartum haemorrhage	JA43	Approved	[3]

Misoprostol Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Prostacyclin receptor (PTGIR)	TTOFYT1	PI2R_HUMAN	Antagonist	[8]

Misoprostol Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Interleukin-23 subunit alpha (IL23A)	OTYO99HC	IL23A_HUMAN	Increases Expression	[9]

Indication(s) of Oxytocin

Disease Entry	ICD 11	Status	REF
Autism spectrum disorder	6A02	Approved	[4]
Ductal breast carcinoma in situ	N.A.	Approved	[5]
Postpartum haemorrhage	JA43	Approved	[5]
Lactation failure	JB46.3	Phase 3	[6]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[7]

Oxytocin Interacts with 4 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Vasopressin V1b receptor (V1BR)	TTL9MHW	V1BR_HUMAN	Agonist	[10]
Vasopressin V2 receptor (V2R)	TTK8R02	V2R_HUMAN	Agonist	[11]
Vasopressin V1a receptor (V1AR)	TT4TFGN	V1AR_HUMAN	Agonist	[12]
Oxytocin receptor (OTR)	TTSCIUP	OXYR_HUMAN	Modulator	[13]

Oxytocin Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Krueppel-like factor 4 (KLF4)	OT4O9RQW	KLF4_HUMAN	Increases Expression	[14]

References

• [1] ClinicalTrials.gov (NCT04004845) Labor Protocol Study
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1936).
• [3] Misoprostol FDA Label
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2174).
• [5] Oxytocin FDA Label
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039450)
• [7] Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 (OsCOVID19)
• [8] Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem. 2003 Feb 28;278(9):6947-58.
• [9] Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med. 2009 Mar 16;206(3):535-48. doi: 10.1084/jem.20082293. Epub 2009 Mar 9.
• [10] The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997 Oct;138(10):4109-22.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368).
• [12] Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem. 1997 Oct 17;272(42):26536-44.
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369).
• [14] Oxytocin inhibits ox-LDL-induced adhesion of monocytic THP-1 cells to human brain microvascular endothelial cells. Toxicol Appl Pharmacol. 2017 Dec 15;337:104-110. doi: 10.1016/j.taap.2017.10.022. Epub 2017 Nov 2.